Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine
Open Access
- 29 April 2025
- journal article
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Abstract
Background: Our knowledge of the presence and type of premonitory symptoms in patients with cluster headache is limited. Methods: Premonitory symptom presence and type in a clinical cohort of cluster headache and migraine was collated retrospectively from clinical notes, alongside a cluster headache nitroglycerin triggered experimental group and an age-matched migraine nitroglycerin experimental group. Demographic data and premonitory symptoms in cluster headache and migraine patients were analysed. The primary focus was on premonitory symptom presence and phenotype in cluster headache patients, with secondary analysis exploring associated factors and comparing spontaneous and nitroglycerin-triggered symptoms in cluster headache and migraine cohorts. Results: Among 164 cluster headache patients, 122/164 (74%) males, aged 45.9 ± 13.8 years (mean ± SD), 66/164 (40%) had chronic cluster headache and 32/164 (20%) had also comorbid migraine. Among them, 85% exhibited premonitory symptoms for which the presence was associated with oxygen treatment. No significant differences were found in symptom frequency between cluster headache and migraine cohorts or within spontaneous and nitroglycerin-triggered symptoms. Conclusions: This study highlights recognizable spontaneous and nitroglycerin-triggered premonitory symptoms in cluster headache and factors potentially impacting cluster headache management, which may aid in tailoring treatment strategies for both conditions through the use of treatment prediction and early intervention.Keywords
Funding Information
- Instituto de Salud Carlos III (CM21/00178)
- Instituto de Salud Carlos III (JR23/00005)
- Instituto de Salud Carlos III (PI24/01085)
This publication has 29 references indexed in Scilit:
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USAThe Lancet, 2023
- Insights into migraine attacks from neuroimagingThe Lancet Neurology, 2023
- Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trialThe Lancet Neurology, 2023
- Biomarkers of Migraine and Cluster Headache: Differences and SimilaritiesAnnals of Neurology, 2023
- Are some patient-perceived migraine triggers simply early manifestations of the attack?Journal of Neurology, 2021
- Biological insights from the premonitory symptoms of migraineNature Reviews Neurology, 2018
- World Medical Association Declaration of HelsinkiJAMA, 2013
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Hypothalamic activation in cluster headache attacksThe Lancet, 1998
- Premonitory and Prodromal Symptoms in Cluster HeadacheCephalalgia, 1998